SEC Comment Letter 0000000000-22-013342 to Aridis Pharmaceuticals, Inc. (ARDS) (CIK 0001614067)
Aridis Pharmaceuticals, Inc. (ARDS) (CIK 0001614067)
Date: Dec. 12, 2022 · CIK: 0001614067 · Accession: 0000000000-22-013342
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-268701
Letter
United States securities and exchange commission logo December 12, 2022 Vu Truong Chief Executive Officer Aridis Pharmaceuticals, Inc. 983 University Avenue, Bldg. B Los Gatos, California 95032 Re:Aridis Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed December 7, 2022 File No. 333-268701 Dear Vu Truong: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
December 12, 2022
Vu Truong
Chief Executive Officer
Aridis Pharmaceuticals, Inc.
983 University Avenue, Bldg. B
Los Gatos, California 95032
Re:Aridis Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed December 7, 2022
File No. 333-268701
Dear Vu Truong:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences